Biotron Inkomsten in het verleden
Verleden criteriumcontroles 0/6
Biotron's earnings have been declining at an average annual rate of -2.6%, while the Biotechs industry saw earnings growing at 12.6% annually. Revenues have been growing at an average rate of 22.9% per year.
Belangrijke informatie
-2.6%
Groei van de winst
6.0%
Groei van de winst per aandeel
Biotechs Groei van de industrie | 9.6% |
Inkomstengroei | 22.9% |
Rendement op eigen vermogen | n/a |
Nettomarge | -208.9% |
Laatste winstupdate | 30 Jun 2024 |
Recente prestatie-updates uit het verleden
Geen updates
Recent updates
Here's Why We're Not Too Worried About Biotron's (ASX:BIT) Cash Burn Situation
Feb 27We Think Biotron (ASX:BIT) Can Afford To Drive Business Growth
Oct 20We're Not Worried About Biotron's (ASX:BIT) Cash Burn
Jul 06Will Biotron (ASX:BIT) Spend Its Cash Wisely?
Jan 18Will Biotron (ASX:BIT) Spend Its Cash Wisely?
Jul 06Here's Why We're Watching Biotron's (ASX:BIT) Cash Burn Situation
Mar 17Here's Why We're Not Too Worried About Biotron's (ASX:BIT) Cash Burn Situation
Nov 27Biotron (ASX:BIT) Is In A Good Position To Deliver On Growth Plans
May 26We're Not Very Worried About Biotron's (ASX:BIT) Cash Burn Rate
Feb 10What Can We Conclude About Biotron's (ASX:BIT) CEO Pay?
Dec 19Opbrengsten en kosten
Hoe Biotron geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
---|---|---|---|---|
30 Jun 24 | 2 | -3 | 1 | 4 |
31 Mar 24 | 2 | -4 | 1 | 4 |
31 Dec 23 | 2 | -4 | 1 | 4 |
30 Sep 23 | 2 | -4 | 2 | 4 |
30 Jun 23 | 1 | -3 | 2 | 3 |
31 Mar 23 | 2 | -3 | 1 | 3 |
31 Dec 22 | 3 | -2 | 1 | 3 |
30 Sep 22 | 2 | -2 | 1 | 3 |
30 Jun 22 | 2 | -3 | 1 | 3 |
31 Mar 22 | 1 | -3 | 1 | 3 |
31 Dec 21 | 1 | -3 | 1 | 3 |
30 Sep 21 | 1 | -3 | 1 | 3 |
30 Jun 21 | 1 | -3 | 1 | 3 |
31 Mar 21 | 1 | -4 | 1 | 3 |
31 Dec 20 | 1 | -4 | 1 | 3 |
30 Sep 20 | 1 | -4 | 1 | 3 |
30 Jun 20 | 1 | -4 | 1 | 3 |
31 Mar 20 | 0 | -3 | 1 | 2 |
31 Dec 19 | 0 | -3 | 1 | 2 |
30 Sep 19 | 1 | -3 | 1 | 2 |
30 Jun 19 | 1 | -2 | 1 | 1 |
31 Mar 19 | 1 | -2 | 1 | 1 |
31 Dec 18 | 1 | -2 | 1 | 1 |
30 Sep 18 | 1 | -2 | 1 | 1 |
30 Jun 18 | 2 | -2 | 1 | 2 |
31 Mar 18 | 2 | -1 | 1 | 2 |
31 Dec 17 | 3 | -1 | 1 | 3 |
30 Sep 17 | 2 | -2 | 1 | 3 |
30 Jun 17 | 2 | -3 | 1 | 3 |
31 Mar 17 | 2 | -3 | 1 | 3 |
31 Dec 16 | 2 | -2 | 1 | 2 |
30 Sep 16 | 2 | -3 | 1 | 3 |
30 Jun 16 | 2 | -3 | 1 | 3 |
31 Mar 16 | 2 | -3 | 1 | 3 |
31 Dec 15 | 2 | -3 | 1 | 3 |
30 Sep 15 | 2 | -3 | 1 | 3 |
30 Jun 15 | 2 | -3 | 1 | 3 |
31 Mar 15 | 2 | -3 | 1 | 3 |
31 Dec 14 | 2 | -3 | 1 | 3 |
30 Sep 14 | 2 | -3 | 1 | 3 |
30 Jun 14 | 2 | -3 | 1 | 3 |
31 Mar 14 | 1 | -4 | 1 | 3 |
31 Dec 13 | 1 | -4 | 1 | 4 |
Kwaliteitswinsten: BIT is currently unprofitable.
Groeiende winstmarge: BIT is currently unprofitable.
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: BIT is unprofitable, and losses have increased over the past 5 years at a rate of 2.6% per year.
Versnelling van de groei: Unable to compare BIT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Winst versus industrie: BIT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (2.5%).
Rendement op eigen vermogen
Hoge ROE: BIT's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.